Saturday, October 31, 2026

Genworth Financial Stock Is 22% Down In The Last 10 Sessions

Genworth Financial Stock Is 22% Down In The Last 10 Sessions

(VIANEWS) - Shares of Genworth Financial (NYSE: GNW) dropped by a staggering 22.12% in 10 sessions from $6.23 to $4.85 at 13:41 EST on Friday, following the last session's upward trend. NYSE is falling 1.44% to $14,617.43, following the last session's upward trend.

Genworth Financial's last close was $5.03, 21.41% under its 52-week high of $6.40.

About Genworth Financial

Genworth Financial, Inc. provides insurance products in the United States and internationally. The company operates in three segments: Enact, U.S. Life Insurance, and Runoff. The Enact segment offers mortgage insurance products primarily insuring prime-based, individually underwritten residential mortgage loans; and pool mortgage insurance products. The U.S. Life Insurance segment offers long-term care insurance products; and service traditional life insurance and fixed annuity products in the United States. The Runoff segment includes variable annuity, variable life insurance, and corporate-owned life insurance, as well as funding agreements. It distributes its products through sales force, in-house sales representatives, and digital marketing programs. The company was founded in 1871 and is headquartered in Richmond, Virginia.

Earnings Per Share

As for profitability, Genworth Financial has a trailing twelve months EPS of $0.84.

PE Ratio

Genworth Financial has a trailing twelve months price to earnings ratio of 5.77. Meaning, the purchaser of the share is investing $5.77 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.47%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Genworth Financial's stock is considered to be overbought (>=80).

Volatility

Genworth Financial's last week, last month's, and last quarter's current intraday variation average was a negative 7.89%, a negative 1.82%, and a positive 2.01%.

Genworth Financial's highest amplitude of average volatility was 7.89% (last week), 3.00% (last month), and 2.01% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth grew by 9.2%, now sitting on 7.51B for the twelve trailing months.

Growth Estimates Quarters

The company's growth estimates for the current quarter and the next is a negative 31% and a negative 25.7%, respectively.

More news about Genworth Financial (GNW).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com